A phase III trial of Halaven (eribulin) in patients with soft tissue sarcoma demonstrated a statistically significant extension in overall survival over the comparator treatment dacarbazine, the primary endpoint of the study. No other systemic treatment for locally advanced or metastatic soft tissue sarcoma has been reported to extend overall survival in a phase III study, according to Halaven’s sponsor, Eisai.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
